Introduction/Background Endometrial cancer is the sixth most common malignancy in women worldwide. With an annual incidence of 1%–2%, the disease is rising. There are 417,000 new instances of endometrial cancer worldwide. Surgical staging of nodal status is essential for endometrial cancer diagnosis and therapy. Systematic lymphadenectomy, which evaluates all lymph nodes, has been the recommended staging procedure for years. After surgery, it increases morbidity and significant consequences. To avoid lymphadenectomy's disadvantages, sentinel lymph node(SLN) biopsy has been studied for staging.

Methodology We evaluated 23 cases of endometrial cancer that underwent treatment at our clinic using robotic surgery and the sentinel node mapping using Indocian green.

Results Patients in the study averaged 56.85 years old. Every instance was operated on robotically, and Indocian green-identified sentinel lymph nodes assessed lymph node status. Three of the twenty-three cases were endometrial serous carcinoma, one clear cell carcinoma, and the remainder endometrioid. The cases were FIGO IA or IB staged. Three Indocian green injections did not stain. One patient had a lymph node block and abscessed node, therefore staining was confined on the right. Bilateral lymphadenectomy was chosen in all patients. Three patients (13.04%) had positive sentinel nodes on frozen sections. Three of the twenty-three suffered radiochemotherapy-managed relapses.

Conclusion Indocyanine green-traced sentinel lymph node mapping is becoming the best way to examine endometrial cancer patients' lymph nodes. It detects nodal metastases with excellent accuracy and reduces surgical morbidity without compromising oncological safety. Endometrial cancer therapy is developing swiftly, and surgeons are adopting SLN mapping to perform precise surgery. A lot of research shows that SLN mapping and biopsy with ultrastaging may safely and reliably diagnose lymph node metastasis, saving unnecessary systematic lymphadenectomy and improving patient quality of life.

Disclosures None.